Histogen, Inc. (HSTO)

NASDAQ: HSTO · IEX Real-Time Price · USD
2.32
-0.02 (-0.85%)
At close: Jun 24, 2022 3:57 PM
2.22
-0.10 (-4.31%)
After-hours: Jun 24, 2022 4:56 PM EDT
-0.85%
Market Cap 5.79M
Revenue (ttm) 4.36M
Net Income (ttm) -11.35M
Shares Out 2.50M
EPS (ttm) -5.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jun 3, 2022
Volume 43,664
Open 2.38
Previous Close 2.34
Day's Range 2.28 - 2.52
52-Week Range 2.06 - 22.80
Beta -0.17
Analysts Buy
Price Target 45.90 (+1,878.4%)
Earnings Date Aug 10, 2022

About HSTO

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, whi... [Read more...]

Industry Biotechnology
CEO Steven Mento
Employees 22
Stock Exchange NASDAQ
Ticker Symbol HSTO
Full Company Profile

Financial Performance

In 2021, Histogen's revenue was $1.03 million, a decrease of -49.88% compared to the previous year's $2.06 million. Losses were -$14.95 million, -20.35% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for HSTO stock is "Buy." The 12-month stock price forecast is 45.9, which is an increase of 1,878.45% from the latest price.

Price Target
$45.9
(1,878.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Histogen Announces 1-for-20 Reverse Stock Split

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective...

Histogen to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective ...

Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

Received $3.75 Million Payment from Allergan

CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D.

SAN DIEGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: PARACRINE ANNOUNCES APPOINTMENT OF BIOTECH VETERAN DAVID...

Paracrine Announces Appointment of Biotech Veteran David Crean, Ph.D. to the Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, announced today the appointment of David Crean, Ph...

Histogen to Report First Quarter 2022 Financial Results and Provide Business Update

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selectiv...

5 Top Biotech Penny Stocks Under $1 To Watch This Week

Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information...

Other symbols: AFIBBBIIDRASYN

Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today

Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...

Other symbols: AGRXQLGN

Histogen Announces Closing of $4.75 Million Private Placement

SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natura...

Histogen Announces $4.75 Million Private Placement

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natura...

Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoi...

Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...

Histogen Announces Closing of $3.5 Million Private Placement

SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural...

Histogen Announces $3.5 Million Private Placement

SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural...

Histogen Reports Third Quarter 2021 Earnings and Provides Business Update

Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee On- Going with Top-Line Data Expected in the Second Half of 2022

Histogen Announces CEO Transition

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, A...

Phase 1 Study in Mild COVID-19 Patients Demonstrated a Favorable Safety and Tolerability Profile and Statistically Significant Clinical Symptom and Biomarker Improvements

Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols: AVIRNRBONVIVPRVBSYNSQL

Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September

Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?

Other symbols: CEISONN

Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

Histogen Shares Additional Emricasan Data From COVID-19 Study

Histogen Inc (NASDAQ: HSTO) and its partner Amerimmune LLC have announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients. As previously reported, emricasan...

Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19...

Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression

Histogen Reports Second Quarter 2021 Earnings and Provides Business Update

Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates

Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...